Arylamine N-Acetyltransferases - from Drug Metabolism and Pharmacogenetics to Identification of Novel Targets for Pharmacological Intervention

Advances in Pharmacology

Volumn 63, Issue , 2012, Pages 169-205

  Sim, Edith ^a,b   Fakis, Giannoulis ^c   Laurieri, Nicola ^a   Boukouvala, Sotiria ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b KINGSTON UNIVERSITY   (United Kingdom)

^c DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A; AROMATIC AMINE; ARYLAMINE ACETYLTRANSFERASE; HYDRAZINE DERIVATIVE; ISOENZYME;

ACETYLATION; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL METABOLISM; BREAST CANCER; CHEMICAL REACTION; DNA POLYMORPHISM; DRUG METABOLISM; DRUG TARGETING; ENZYME BINDING; ENZYME INHIBITION; ENZYME MECHANISM; EUKARYOTE; FETUS DEVELOPMENT; GENE CONTROL; GENE EXPRESSION; GENETIC MANIPULATION; HUMAN; METABOLITE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PROKARYOTE; PROTEIN FUNCTION;

EID: 84863762626     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-398339-8.00005-7     Document Type: Chapter

References (170)

1. Abuhammad A., Lack N., Schweichler J., Staunton D., Sim R.B., Sim E. Improvement of the expression and purification of Mycobacterium tuberculosis arylamine N-acetyltransferase (TBNAT) a potential target for novel anti-tubercular agents. Protein Expression and Purification 2011, 80:246-252.
2. Abu-Zeid M., Nagata K., Miyata M., Ozawa S., Fukuhara M., Yamazoe Y., et al. An arylamine acetyltransferase (AT-I) from Syrian golden hamster liver: cloning, complete nucleotide sequence, and expression in mammalian cells. Molecular Carcinogenesis 1991, 4:81-88.
3. Adam P.J., Berry J., Loader J.A., Tyson K.L., Craggs G., Smith P., et al. Arylamine N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro. Molecular Cancer Research 2003, 1:826-835.
4. Anderton M.C., Bhakta S., Besra G.S., Jeavons P., Eltis L.D., Sim E. Characterization of the putative operon containing arylamine N-acetyltransferase (NAT) in Mycobacterium bovis BCG. Molecular Microbiology 2006, 59:181-192.
5. Andres H.H., Klem A.J., Schopfer L.M., Harrison J.K., Weber W.W. On the active site of liver acetyl-CoA. Arylamine N-acetyltransferase from rapid acetylator rabbits (iii/j). Journal of Biological Chemistry 1988, 263:7521-7527.
6. Andres H.H., Kolb H.J., Schreiber R.J., Weiss L. Characterization of the active site, substrate specificity and kinetic properties of acetyl-CoA:arylamine N-acetyltransferase from pigeon liver. Biochimica et Biophysica Acta 1983, 746:193-201.
7. Andres H.H., Vogel R.S., Tarr G.E., Johnson L., Weber W.W. Purification, physicochemical, and kinetic properties of liver acetyl-CoA:arylamine N-acetyltransferase from rapid acetylator rabbits. Molecular Pharmacology 1987, 31:446-456.
8. Ballester P.J., Westwood I., Laurieri N., Sim E., Richards W.G. Prospective virtual screening with Ultrafast Shape Recognition: the identification of novel inhibitors of arylamine N-acetyltransferases. Journal of the Royal Society Interface 2010, 7:335-342.
9. Barker D.F., Husain A., Neale J.R., Martini B.D., Zhang X., Doll M.A., et al. Functional properties of an alternative, tissue-specific promoter for human arylamine N-acetyltransferase 1. Pharmacogenetics and Genomics 2006, 16:515-525.
10. Bhakta S., Besra G.S., Upton A.M., Parish T., Sholto-Douglas-Vernon C., Gibson K.J., et al. Arylamine N-acetyltransferase is required for synthesis of mycolic acids and complex lipids in Mycobacterium bovis BCG and represents a novel drug target. Journal of Experimental Medicine 2004, 199:1191.
11. Blum M., Demierre A., Grant D.M., Heim M., Meyer U.A. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proceedings of the National Academy of Sciences of the USA 1991, 88:5237-5241.
12. Blum M., Grant D.M., McBride W., Heim M., Meyer U.A. Human arylamine N-acetyltransferase genes: Isolation, chromosomal localization, and functional expression. DNA and Cell Biology 1990, 9:193-203.
13. Boukouvala S., Fakis G. Arylamine N-acetyltransferases: what we learn from genes and genomes. Drug Metabolism Reviews 2005, 37:511-564.
14. Boukouvala S., Sim E. Structural analysis of the genes for human arylamine N-acetyltransferases and characterization of alternative transcripts. Basic and Clinical Pharmacology and Toxicology 2005, 96:343-351.
15. Boukouvala S., Price N., Plant K.E., Sim E. Structure and transcriptional regulation of the Nat2 gene encoding for the drug-metabolising enzyme arylamine N-acetyltransferase type 2 in mice. Biochemical Journal 2003, 375:593-602.
16. Boukouvala S., Price N., Sim E. Identification and functional characterization of novel polymorphisms associated with the genes for arylamine N-acetyltransferases in mice. Pharmacogenetics 2002, 12:385-394.
17. Boukouvala S., Westwood I.M., Butcher N.J., Fakis G. Current trends in N-acetyltransferase research arising from the 2007 International NAT workshop. Pharmacogenomics 2008, 9:765-771.
18. Brans R., Laizane D., Khan A., Blömeke B. N-acetyltransferase 2 genotyping: an accurate and feasible approach for simultaneous detection of the most common NAT2 alleles. Clinical Chemistry 2004, 50:1264-1266.
19. Brooke E.W., Davies S.G., Mulvaney A.W., Pompeo F., Sim E., Vickers R.J. An approach to identifying novel substrates of bacterial arylamine N-acetyltransferases. Bioorganic and Medicinal Chemistry 2003, 11:1227-1234.
20. Butcher N.J., Minchin R.F. Arylamine N-acetyltransferase 1 gene regulation by androgens requires a conserved heat shock element for heat shock factor-1. Carcinogenesis 2010, 31:820-826.
21. Butcher N.J., Arulpragasam A., Goh H.L., Davey T., Minchin R.F. Genomic organization of human arylamine N-acetyltransferase type I reveals alternative promoters that generate different 5'-UTR splice variants with altered translational activities. Biochemical Journal 2005, 387:119-127.
22. Butcher N.J., Tetlow N.L., Cheung C., Broadhurst G.M., Minchin R.F. Induction of human arylamine N-acetyltransferase type I by androgens in human prostate cancer cells. Cancer Research 2007, 67:85-92.
23. Butcher N.J., Tiang J., Minchin R.F. Regulation of arylamine N-acetyltransferases. Current Drug Metabolism 2008, 9:498-504.
24. Cao W., Chau B., Hunter R., Strnatka D., McQueenm C.A., Erickson R.P. Only low levels of exogenous N-acetyltransferase can be achieved in transgenic mice. Pharmacogenomics Journal 2005, 5:255-261.
25. Cao W., Strnatka D., McQueen C.A., Hunter R.J., Erickson R.P. N-acetyltransferase 2 activity and folate levels. Life Sciences 2010, 86:103-106.
26. Cartwright R.A., Glasham R.W., Rogers H.J., Ahmad R.A., Barham-Hall D., Higgins E., et al. Role of N-acetyltransferase phenotypes in bladder carcinogenesis:a pharmacogenetic epidemiological approach to bladder cancer. Lancet 1982, 2:842-845.
27. Coelho M.B., Costa E.R., Vasconcellos S.E., Linck N., Ramos R.M., Amorim H.L., et al. Sequence and structural characterization of tbNAT gene in isoniazid-resistant Mycobacterium tuberculosis: identification of new mutations. Mutation Research 2011, 712:33-39.
28. Cornish V.A., Pinter K., Boukouvala S., Johnson N., Labrousse C., Payton M., et al. Generation and analysis of mice with a targeted disruption of the arylamine N-acetyltransferase type 2 gene. Pharmacogenomics Journal 2003, 3:169-177.
29. Dairou J., Laurieri N., Sim E., Rodriges-Lima F. Uncoupled reaction of N-acetylation and AcCoA hydrolysis 2010, International NAT Workshop, Paris, France.
30. Dairou J., Malecaze F., Dupret J.M., Rodrigues-Lima F. The xenobiotic-metabolizing enzymes arylamine N-acetyltransferases in human lens epithelial cells: inactivation by cellular oxidants and UVB-induced oxidative stress. Molecular Pharmacology 2005, 67:1299-1306.
31. Dairou J., Petit E., Ragunathan N., Baeza-Squiban A., Marana F., Dupret J.-M., et al. Arylamine N-acetyltransferase activity in bronchial epithelial cells and its inhibition by cellular oxidants. Toxicology and Applied Pharmacology 2009, 236:366-371.
32. Deguchi T. Sequences and expression of alleles of polymorphic arylamine N-acetyltransferase of human liver. Journal of Biological Chemistry 1992, 267:18,140-18,147.
33. Deguchi T., Mashimo M., Suzuki T. Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver. Journal of Biological Chemistry 1990, 265:12,757-12,760.
34. Delgoda R., Lian L.Y., Sandy J., Sim E. NMR investigation of the catalytic mechanism of arylamine N-acetyltransferase from Salmonella typhimurium. Biochimicaet Biophysica Acta 2003, 1620:8-14.
35. Delomenie C., Fouix S., Longuemaux S., Brahimi N., Bizet C., Picard B., et al. Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid. Journal of Bacteriology 2001, 183:3417-3427.
36. Doll M.A., Hein D.W.. Comprehensive human NAT2 genotype method using single nucleotide polymorphism-specific polymerase chain reaction primers and fluorogenic probes. Analytical Biochemistry 2001, 288:106-108.
37. Doll M.A., Hein D.W. Rapid genotype method to distinguish frequent and/or functional polymorphisms in human N-acetyltransferase-1. Analytical Biochemicstry 2002, 301:328-332.
38. Dupret J.M., Grant D.M. Site-directed mutagenesis of recombinant human arylamine N-acetyltransferase expressed in Escherichia coli. Evidence for direct involvement of Cys68 in the catalytic mechanism of polymorphic human NAT2. Journal of Biological Chemistry 1992, 267:7381-7385.
39. Erickson R.P. Genes, environment, and orofacial clefting: N-acetyltransferase and folic acid. Journal of Craniofacial Surgery 2010, 21:1384-1387.
40. Erickson R.P., Cao W., Acuña D.K., Strnatka D.W., Hunter R.J., Chau B.T., et al. Confirmation of the role of N-acetyltransferase 2 in teratogen-induced cleft palate using transgenics and knockouts. Molecular Reproduction and Development 2008, 75:1071-1076.
41. Evans D.A., Manley K.A., McKuisick V.A. Genetic control of isoniazid acetylation in man. British Medical Journal 1960, 2:485-491.
42. Fakis G., Boukouvala S., Buckle V., Payton M., Denning C., Sim E. Chromosomal localisation and mapping of the genes for murine arylamine N-acetyltransferases (NATs), enzymes involved in the metabolism of carcinogens: Identification of a novel upstream non-coding exon for murine Nat2. Cytogenetics and Cell Genetics 2000, 90:134-138.
43. Fakis G., Boukouvala S., Kawamura A., Kennedy S Description of a novel polymorphic gene encoding for arylamine N-acetyltransferase in the rhesus macaque (Macaca mulatta), a model animal for endometriosis. Pharmacogenetics and Genomics 2007, 17:181-188.
44. Franke S., Klowitz I., Schnakenberg E., Rommel B., van den Ven W., Bullerdiek J., et al. Isolation and mapping of a cosmid clone containing the human NAT2 gene. Biochemical and Biophysical Research Communications 1994, 199:1672-1675.
45. Fullam E., Abuhammad A., Wilson D.L., Anderton M.C., Davies S.G., Russell A.J., et al. Analysis of β-amino alcohols as inhibitors of the potential anti-tubercular target N-acetyltransferase. Bioorganic and Medicinal Chemistry Letters 2011, 21:1185-1190.
46. Fullam E., Kawamura A., Wilkinson H., Abuhammad A., Westwood I., Sim E. Comparison of the arylamine N-acetyltransferase from Mycobacterium marinum and Mycobacterium tuberculosis. Protein Journal 2009, 28:281-293.
47. Fullam E., Westwood I.M., Anderton M.C., Lowe E.D., Sim E., Noble M.E. Divergence of cofactor recognition across evolution: Coenzyme A binding in a prokaryotic arylamine N-acetyltransferase. Journal of Molecular Biology 2008, 375:178-191.
48. García-Closas M., Hein D.W., Silverman D., Malats N., Yeager M., Jacobs K., et al. A single nucleotide polymorphism tags variation in the arylamine N-acetyltransferase 2 phenotype in populations of European background. Pharmacogenetics and Genomics 2011, 21:231-236.
49. Glenn A.E., Bacon C.W. FDB2 encodes a member of the arylamine N-acetyltransferase family and is necessary for biotransformation of benzoxazolinones by Fusarium verticillioides. Journal of Applied Microbiology 2009, 107:657-671.
50. Glenn A.E., Gold S.E., Bacon C.W. Fdb1 and Fdb2, Fusarium verticillioides loci necessary for detoxification of preformed antimicrobials from corn. Molecular Plant-Microbe Interactions 2002, 15:91-101.
51. Glenn A.E., Hinton D.M., Yates I.E., Bacon C.W. Detoxification of corn antimicrobial compounds as the basis for isolating Fusarium verticillioides and some other Fusarium species from corn. Applied and Environmental Microbiology 2001, 67:2973-2981.
52. Glenn A.E., Karagianni E.P., Ulndreaj A., Boukouvala S Comparative genomic and phylogenetic investigation of the xenobiotic metabolizing arylamine N-acetyltransferase enzyme family. FEBS Letters 2010, 584:3158-3164.
53. Glenn A.E., Meredith F.I., Morrison W.H., Bacon C.W. Identification of intermediate and branch metabolites resulting from biotransformation of 2-benzoxazolinone by Fusarium verticillioides. Applied and Environmental Microbiology 2003, 69:3165-3169.
54. Goodfellow G.H., Dupret J.M., Grant D.M. Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2. Biochemical Journal 2000, 348:159-166.
55. Hein D.W., Bendaly J., Neale J.R., Doll M.A. Systemic functional expression of N-acetyltransferase polymorphism in the F344 Nat2 congenic rat. Drug Metabolism and Disposition 2008, 36:2452-2459.
56. Hein D.W., Boukouvala S., Grant D.M., Minchin R.F., Sim E. Changes in consensus arylamine N-acetyltransferase gene nomenclature. Pharmacogenetics and Genomics 2008, 18:367-368.
57. Hickman D., Risch A., Buckle V., Spurr N.K., Jeremiah S.J., McCarthy A., et al. Chromosomal localisation of human genes for arylamine N-acetyltransferase. Biochemical Journal 1994, 297:441-445.
58. Holton S.J., Dairou J., Sandy J., Rodrigues-Lima F., Dupret J.M., Noble M.E., et al. Structure of Mesorhizobium loti arylamine N-acetyltransferase 1. Acta Crystallographica Section F: Structural Biology and Crystallization Communincations 2005, 61:14-16.
59. Husain A., Barker D.F., States J.C., Doll M.A., Hein D.W.. Identification of the major promoter and non-coding exons of the human arylamine N-acetyltransferase 1 gene (NAT1). Pharmacogenetics 2004, 14:397-406.
60. Husain A., Zhang X., Doll M.A., States J.C., Barker D.F., Hein D.W. Functional analysis of the human N-acetyltransferase 1 major promoter: quantitation of tissue expression and identification of critical sequence elements. Drug Metabolism and Disposition 2007, 35:1649-1656.
61. Husain A., Zhang X., Doll M.A., States J.C., Barker D.F., Hein D.W. Identification of N-acetyltransferase 2 (NAT2) transcription start sites and quantitation of NAT2-specific mRNA in human tissues. Drug Metabolism and Disposition 2007, 35:721-727.
62. Ilett K.F., Kadlubar F.F., Minchin R.F. 1998 International Meeting on the arylamine N-Acetyltransferases: synopsis of the workshop on nomenclature, biochemistry, molecular biology, interspecies comparisons, and role in human disease risk. Drug Metabolism and Disposition 1999, 27:957-959.
63. Jefferson F.A., Xiao G.H., Hein D.W. 4-Aminobiphenyl downregulation of NAT2 acetylator genotype-dependent N- and O-acetylation of aromatic and heterocyclic amine carcinogens in primary mammary epithelial cell cultures from rapid and slow acetylator rats. Toxicological Science 2009, 107:293-297.
64. Jencks W.P., Gresser M., Valenzuela M.S., Huneeus F.C. Acetyl-Coenzyme A: Arylamine acetyltransferase measurement of the steady state concentration of the acetyl-enzyme intermediate. Journal of Biological Chemistry 1972, 247:3756-3760.
65. Jenne J.W. Partial purification and properties of the isoniazid transacetylase in human liver. Its relationship to the acetylation of p-aminosalicylic acid. Journal of Clinical Investigation 1965, 44:1992-2002.
66. Kawamura A. Studies on Hamster Arylamine N-acetyltransferase 2003, University of Oxford, UK, D. Phil. thesis.
67. Kawamura A., Graham J., Mushtaq A., Tsiftsoglou S.A., Vath G.M., Hanna P.E., et al. Eukaryotic arylamine N-acetyltransferase. Investigation of substrate specificity by high-throughput screening. Biochemical Pharmacology 2005, 69:347-359.
68. Kawamura A., Westwood I., Wakefield L., Long H., Zhang N., Walters K., et al. Mouse N-acetyltransferase type 2, the homologue of human N-acetyltransferase type 1. Biochemical Pharmacology 2008, LL75:1550-1560.
69. Kelly S.L., Sim E. Expression of N-acetyltransferase in a human monocytic cell line, U937. Human and Experimental Toxicology 1991, 10:33-38.
70. Kim S.J., Kang H.S., Chang H.L., Jung Y.C., Sim H.B., Lee K.S., et al. Promoter hypomethylation of the N-acetyltransferase 1 gene in breast cancer. Oncology Reports 2008, 19:663-668.
71. Kim S.J., Kang H.S., Jung S.Y., Min S.Y., Lee S., Kim S.W., et al. Methylation patterns of genes coding for drug-metabolizing enzymes in tamoxifen-resistant breast cancer tissues. Journal of Molecular Medicine (Berlin) 2010, 88:1123-1131.
72. King N., Westbrook M.J., Young S.L., Kuo A., Abedin M., Chapman J., et al. The genome of the choanoflagellate Monosiga brevicollis and the origin of metazoans. Nature 2008, 451:783-788.
73. Kulik T., Pszczółkowska A., Lojko M. Multilocus phylogenetics show high intraspecific variability within Fusarium avenaceum. International Journal of Molecular Science 2011, 12:5626-5640.
74. Lack N., Kawamura A., Fullam E., Laurieri N., Beard S., Russell A.J., et al. Temperature stability of proteins essential for the intracellular survival of Mycobacterium tuberculosis. Biochemical Journal 2009, 418:369-378.
75. Lack N.A., Yam K.C., Lowe E.D., Horsman G.P., Owen R.L., Sim E., et al. Characterization of a carbon-carbon hydrolase from Mycobacterium tuberculosis involved in cholesterol metabolism. Journal of Biological Chemistry 2010, 285:434-443.
76. Laurieri N., Crawford M.H., Kawamura A., Westwood I.M., Robinson J., Fletcher A.M., et al. Small molecule colorimetric probes for specific detection of human arylamine N-acetyltransferase 1, a potential breast cancer biomarker. Journal of the American Chemical Society 2010, 132:3238-3239.
77. Leff M.A., Epstein P.N., Doll M.A., Fretland A.J., Devanboyina U.S., Rustan T.D., et al. Prostate-specific human N-acetyltransferase 2 (NAT2) expression in the mouse. Journal of Pharmacology and Experimental Therapeutics 1999, 290:182-187.
78. Levy G.N., Weber W.W. 2-Aminofluorene-DNA adducts in mouse urinary bladder: effect of age, sex and acetylator phenotype. Carcinogenesis 1992, 13:159-164.
79. Levy G.N., Chung J.G., Weber W.W. 2-Aminofluorene metabolism and DNA adduct formation by mononuclear leukocytes from rapid and slow acetylator mouse strains. Carcinogenesis 1994, 15:353-357.
80. Li J., Zhang L., Zhou H., Stoneking M., Tang K. Global patterns of genetic diversity and signals of natural selection for human ADME genes. Human Molecular Genetics 2011, 20:528-540.
81. Lipmann F. Acetylation of sulfanilamide by liver homogenates and extracts. Journal of Biological Chemistry 1945, 160:173-190.
82. Liu F., Zhang N., Zhou X., Hanna P.E., Wagner C.R., Koepp D.M., et al. Arylamine N-acetyltransferase aggregation and constitutive ubiquitylation. Journal of Molecular Biology 2006, 361:482-492.
83. Liu L., Wagner C.R., Hanna P.E. Isoform-selective inactivation of human arylamine N-acetyltransferases by reactive metabolites of carcinogenic arylamines. Chemical Research in Toxicology 2009, 22:1962-1974.
84. Loehle J.A., Cornish V., Wakefield L., Doll M.A., Neale J.R., Zang Y., et al. N-acetyltransferase (NAT) 1 and 2 expression in Nat2 knockout mice. Journal of Pharmacology and Experimental Therapeutics 2006, 319:724-728.
85. Luca F., Bubba G., Basile M., Brdicka R., Michalodimitrakis E., Rickards O., et al. Multiple advantageous amino acid variants in the NAT2 gene in human populations. PLoS One 2008, 3(9):e3136.
86. Magalon H., Patin E., Austerlitz F., Hegay T., Aldashev A., Quintana-Murci L., et al. Population genetic diversity of the NAT2 gene supports a role of acetylation in human adaptation to farming in Central Asia. European Journal of Human Genetics 2008, 16:243-251.
87. Malka F., Dairou J., Ragunathan N., Dupret J.M., Rodrigues-Lima F. Mechanisms and kinetics of human arylamine N-acetyltransferase 1 inhibition by disulfiram. FEBS Journal 2009, 276:4900-4908.
88. Martell K.J., Vatsis K.P., Weber W.W. Molecular genetic basis of rapid and slow acetylation in mice. Molecular Pharmacology 1991, 40:218-227.
89. Martins M., Dairou J., Rodrigues-Lima F., Dupret J.M., Silar P. Insights into the phylogeny or arylamine N-acetyltransferases in fungi. Journal of Molecular Evolution 2010, 71:141-152.
90. Martins M., Pluvinage B., Li de la Sierra-Gallay I., Barbault F., Dairou J., Dupret J.M., et al. Functional and structural characterization of the arylamine N-acetyltransferase from the opportunistic pathogen Nocardia farcinica. Journal of Molecular Biology 2008, 383:549-560.
91. Martins M., Rodrigues-Lima F., Dairou J., Lamouri A., Malagnac F., Silar P., et al. An acetyltransferase conferring tolerance to toxic aromatic amine chemicals: molecular and functional studies. Journal of Biological Chemistry 2009, 284:18,726-18,733.
92. Matas N., Thygesen P., Stacey M., Risch A., Sim E. Mapping AAC1, AAC2 and AACP, the genes for arylamine N-acetyltransferases, carcinogen metabolising enzymes on human chromosome 8p22, a region frequently deleted in tumours. Cytogenetics and Cell Genetics 1997, 77:290-295.
93. McQueen C.A. Summary of the third workshop on arylamine N-acetyltransferases. ISSX Newsletter 2004, 24(3):13.
94. Millner L.M., Doll M.A., Cai J., States J.C., Hein D.W. NATb/NAT1*4 promotes greater arylamine N-acetyltransferase 1 mediated DNA adducts and mutations than NATa/NAT1*4 following exposure to 4-aminobiphenyl. Molecular Carcinogenesis 2011, [Epub ahead of print]. 10.1002/mc.20836.
95. Minchin R.F. Acetylation of p-aminobenzoylglutamate, a folic acid catabolite, by recombinant human arylamine N-acetyltransferase and U937 cells. Biochemical Journal 1995, 307:1-3.
96. Minchin R.F., Hanna P.E., Dupret J.M., Wagner C.R., Rodrigues-Lima F., Butcher N.J. Arylamine N-acetyltransferase I. International Journal of Biochemistry and Cell Biology 2007, 39:1999-2005.
97. Miner M.D., Chang J.C., Pandey A.K., Sassetti C.M., Sherman D.R. Role of cholesterol in Mycobacterium tuberculosis infection. Indian Journal of Experimental Biology 2009, 47:407-411.
98. Mitchell R.S., Bell J.C. Clinical implications of isoniazid, PAS and streptomycin blood levels in pulmonary tuberculosis. Transactions of the American Clinical and Climatological Association 1957, 69:98-102.
99. Moore L.E., Baris D.R., Figueroa J.D., Garcia-Closas M., Karagas M.R., Schwenn M.R., et al. GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: results from the New England bladder cancer study and NAT2 meta-analysis. Carcinogenesis 2011, 32:182-189.
100. Moretti A., Caron L., Nakano A., Lam J.T., Bernshausen A., Chen Y., et al. Multipotent embryonic isl1+ progenitor cells lead to cardiac, smooth muscle, and endothelial cell diversification. Cell 2006, 127:1151-1165.
101. Mortensen H.M., Froment A., Lema G., Bodo J.M., Ibrahim M., Nyambo T.B., et al. Characterization of genetic variation and natural selection at the arylamine N-acetyltransferase genes in global human populations. Pharmacogenomics 2011, 12:1545-1558.
102. Mushtaq A., Payton M., Sim E. The COOH terminus of arylamine N-acetyltransferase from Salmonella typhimurium controls enzymic activity. Journal of Biological Chemistry 2002, 277:12,175-12,181.
103. Ohsako S., Deguchi T. Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases from human liver. Journal of Biological Chemistry 1990, 265:4630-4634.
104. Ohsako S., Ohtomi M., Sakamoto Y., Uyemura K., Deguchi T. Arylamine N-acetyltransferase from chicken liver ii. Cloning of cDNA and expression in chinese hamster ovary cells. Journal of Biological Chemistry 1988, 263:7534-7538.
105. Pandey A.K., Sassetti C.M. Mycobacterial persistence requires the utilization of host cholesterol. Proceedings of the National Academy of Sciences of the USA 2008, 105:4376-4380.
106. Paterson S., Sin K.L., Tiang J.M., Minchin R.F., Butcher N.J. Histone deacetylase inhibitors increase human arylamine N-acetyltransferase-1 expression in human tumor cells. Drug Metabolism and Disposition 2011, 39:77-82.
107. Patin E., Barreiro L.B., Sabeti P.C., Austerlitz F., Luca F., Sajantila A., et al. Deciphering the ancient and complex evolutionary history of human arylamine N-acetyltransferase genes. American Journal of Human Genetics 2006, 78:423-436.
108. Patin E., Harmant C., Kidd K.K., Kidd J., Froment A., Mehdi S.Q., et al. Sub-Saharan African coding sequence variation and haplotype diversity at the NAT2 gene. Human Mutation 2006, 27:720.
109. Payton M., Auty R., Delgoda R., Everett M., Sim E. Cloning and characterization of arylamine N-acetyltransferase genes from mycobacterium smegmatis and Mycobacterium tuberculosis: Increased expression results in isoniazid resistance. Journal of Bacteriology 1999, 181:1343-1347.
110. Payton M., Gifford C., Schartau P., Hagemeier C., Mushtaq A., Lucas S., et al. Evidence towards the role of arylamine N-acetyltransferase in Mycobacterium smegmatis and development of a specific antiserum against the homologous enzyme of Mycobacterium tuberculosis. Microbiology 2001, 147:3295-3302.
111. Payton M., Smelt V., Upton A., Sim E. A method for genotyping murine arylamine N-acetyltransferase type 2 (NAT2): A gene expressed in preimplantation embryonic stem cells encoding an enzyme acetylating the folate catabolite p-aminobenzoylglutamate. Biochemical Pharmacology 1999, 58:779-785.
112. Pluvinage B., Dairou J., Possot O.M., Martins M., Fouet A., Dupret J.M., et al. Cloning and molecular characterization of three arylamine N-acetyltransferase genes from Bacillus anthracis: identification of unusual enzymatic properties and their contribution to sulfamethoxazole resistance. Biochemistry 2007, 46:7069-7078.
113. Pluvinage B., Sierra-Gallay I.L., Kubiak X., Xu X., Dairou J., Dupret J.M., et al. The Bacillus anthracis arylamine N-acetyltransferase ((BACAN)NAT1) that inactivates sulfamethoxazole, reveals unusual structural features compared with the other NAT isoenzymes. FEBS Letters 2011, 585:3947-3952.
114. Pompeo F., Brooke E.W., Kawamura A., Mushtaq A., Sim E. The pharmacogenetics of NAT: structural aspects. Pharmacogenomics 2002, 3:19-30.
115. Ragunathan N., Busi F., Pluvinage B., Sanfins E., Dupret J.M., Rodrigues-Lima F., et al. The human xenobiotic-metabolizing enzyme arylamine N-acetyltransferase 1 (NAT1) is irreversibly inhibited by inorganic (Hg2+) and organic mercury (CH3Hg+): mechanism and kinetics. FEBS Letters 2010, 584:3366-3369.
116. Rengarajan J., Bloom B.R., Rubin E.J. Genome wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages. Proceedings of the National Academy of Sciences of the USA 2005, 102:8327-8332.
117. Riddle B., Jencks W.P.. Acetyl-coenzyme A: Arylamine N-acetyltransferase. Role of the acetyl-enzyme intermediate and the effects of substituents on the rate. Journal of Biological Chemistry 1971, 246:3250-3258.
118. Risch A., Wallace D.M., Bathers S., Sim E. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Human Molecular Genetics 1995, 4:231-236.
119. nd International Workshop on the arylamine Nacetyltransferases. Pharmacogenomics Journal 2002, 2:152-155.
120. Rodrigues-Lima F., Dairou J., Diaz C.L., Rubio M.C., Sim E., Spaink H.P., et al. Cloning, functional expression and characterization of Mesorhizobium loti arylamine N-acetyltransferases: rhizobial symbiosis supplies leguminous plants with the xenobiotic N-acetylation pathway. Molecular Microbiology 2006, 60:505-512.
121. Rodrigues-Lima F., Dairou J., Laurieri N., Busi F., Dupret J.M. Fifth international workshop on arylamine N-acetyltransferases. University Paris Diderot, Paris, France, 1-3 September 2010. Pharmacogenomics 2011, 12:1091-1093.
122. Rothman N., Garcia-Closas M., Chatterjee N., Malats N., Wu X., Figueroa J.D., et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nature Genetics 2010, 42:978-984.
123. Russell A.J., Westwood I.M., Crawford M.H., Robinson J., Kawamura A., Redfield C., et al. Selective small molecule inhibitors of the potential breast cancer marker, human arylamine N-acetyltransferase 1, and its murine homologue, mouse arylamine N-acetyltransferase 2. Bioorganic and Medicinal Chemistry 2009, 17:905-918.
124. Sabbagh A., Darlu P., Crouau-Roy B., Poloni E.S. Arylamine N-acetyltransferase 2 (NAT2) genetic diversity and traditional subsistence: a worldwide population survey. PLoS One 2011, 6(4):e18507.
125. Sabbagh A., Langaney A., Darlu P., Gérard N., Krishnamoorthy R., Poloni E.S. Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history. BMC Genetics 2008, 9:21.
126. Sandy J., Mushtaq A., Holton S.J., Schartau P., Noble M.E., Sim E. Investigation of the catalytic triad of arylamine N-acetyltransferases: Essential residues required for acetyl transfer to arylamines. Biochemical Journal 2005, 390:115-123.
127. Sandy J., Mushtaq A., Kawamura A., Sinclair J., Noble M., Sim E. The structure of arylamine N-acetyltransferase from Mycobacterium smegmatis - an enzyme which inactivates the anti-tubercular drug, isoniazid. Journal of Molecular Biology 2002, 318:1071-1083.
128. Sholto-Douglas-Vernon C., Sandy J., Victor T.C., Sim E., Helden P.D. Mutational and expression analysis of tbNAT and its response to isoniazid. Journal of Medical Microbiology 2005, 54:1189-1197.
129. Sim E., Hickman D. Polymorphism in human N-acetyltransferase - the case of the missing allele. Trends in Pharmacological Science 1991, 12:211-213.
130. Sim E., Lack N., Wang C.J., Long H., Westwood I., Fullam E., et al. Arylamine N-acetyltransferases: structural and functional implications of polymorphisms. Toxicology 2008, 254:170-183.
131. Sim E., Walters K., Boukouvala S. Arylamine N-acetyltransferases: from structure to function. Drug Metabolism Reviews 2008, 40:479-510.
132. Sinclair J.C., Sandy J., Delgoda R., Sim E., Noble M.E. Structure of arylamine N-acetyltransferase reveals a catalytic triad. Nature Structural Biology 2000, 7:560-564.
133. Smelt V.A., Mardon H.J., Sim E. Placental expression of arylamine N-acetyltransferases: evidence for linkage disequilibrium between NAT1*10 and NAT2*4 alleles of the two human arylamine N-acetyltransferase loci NAT1 and NAT2. Pharmacology and Toxicology 1998, 83:149-157.
134. Smelt V.A., Upton A., Adjaye J., Payton M.A., Boukouvala S., Johnson N., et al. Expression of arylamine N-acetyltransferases in pre-term placentas and in human pre-implantation embryos. Human Molecular Genetics 2000, 9:1101-1107.
135. Sneider G. Virtual screening: an endless staircase?. Nature Reviews Drug Discovery 2010, 9:273-276.
136. Stanley L.A., Copp A.J., Pope J., Rolls S., Smelt V., Perry V.H., et al. Immunochemical detection of arylamine N-acetyltransferase during mouse embryonic development and in adult mouse brain. Teratology 1998, 58:174-182.
137. Sugamori K.S., Brenneman D., Grant D.M. Liver-selective expression of human arylamine N-acetyltransferase NAT2 in transgenic mice. Drug Metabolism and Disposition 2011, 39:882-890.
138. Sugamori K.S., Wong S., Gaedigk A., Yu V., Abramovici H., Rozmahel R., et al. Generation and functional characterization of arylamine N-acetyltransferase Nat1/Nat2 double-knockout mice. Molecular Pharmacology 2003, 64:170-179.
139. Tailleux L., Waddell S.J., Pelizzola M., Mortellaro A., Withers M., Tanne A., et al. Probing host pathogen cross-talk by transcriptional profiling of both Mycobacterium tuberculosis and infected human dendritic cells and macrophages. PLoS One 2008, 3(1):e1403.
140. Tiang J.M., Butcher N.J., Cullinane C., Humbert P.O., Minchin R.F. RNAi-mediated knock-down of arylamine N-acetyltransferase-1 expression induces E-cadherin up-regulation and cell-cell contact growth inhibition. PLoS One 2011, 6(2):e17031.
141. Tiang J.M., Butcher N.J., Minchin R.F. Small molecule inhibition of arylamine N-acetyltransferase Type I inhibits proliferation and invasiveness of MDA-MB-231 breast cancer cells. Biochemical and Biophysical Research Communications 2010, 393:95-100.
142. Trepanier L.A., Ray K., Winand N.J., Spielberg S.P., Cribb A.E. Cytosolic arylamine N-acetyltransferase (NAT) deficiency in the dog and other canids due to an absence of NAT genes. Biochemical Pharmacology 1997, 54:73-80.
143. Upton A.M., Mushtaq A., Victor T.C., Sampson S.L., Sandy J., Smith D.M., et al. Arylamine N-acetyltransferase of Mycobacterium tuberculosis is a polymorphic enzyme and a site of isoniazid metabolism. Molecular Microbiology 2001, 42:309-317.
144. Vagena E., Fakis G., Boukouvala S. Arylamine N-acetyltransferases in prokaryotic and eukaryotic genomes: a survey of public databases. Current Drug Metabolism 2008, 9:628-660.
145. Van der Geize R., Heuser T., Yam K., Wilbrink M.H., Hara H., Anderton M.C., et al. A gene cluster encoding cholesterol catabolism in a soil actinomycete provides insight into Mycobacterium tuberculosis survival in macrophages. Proceedings of the National Academy of Sciences of the USA 2007, 104:1947-1952.
146. Wakefield L., Boukouvala S., Sim E. Characterisation of CpG methylation in the upstream control region of mouse Nat2: evidence for a gene-environment interaction in a polymorphic gene implicated in folate metabolism. Gene 2010, 452:16-21.
147. Wakefield L., Cornish V., Broackes-Carter F., Sim E. Arylamine N-acetyltransferase 2 expression in the developing heart. Journal of Histochemistry and Cytochemistry 2005, 53:583-592.
148. Wakefield L., Cornish V., Long H., Griffiths W.J., Sim E. Deletion of a xenobiotic metabolizing gene in mice affects folate metabolism. Biochemical and Biophysical Research Communications 2007, 364:556-560.
149. Wakefield L., Cornish V., Long H., Kawamura A., Zhang X., Hein D.W., et al. Mouse arylamine N-acetyltransferase 2 (NAT2) expression during embryogenesis: A potential marker for the developing neuroendocrine system. Biomarkers 2008, 13:106-118.
150. Wakefield L., Long H., Lack N., Sim E. Ocular defects associated with a null mutation in the mouse arylamine N-acetyltransferase 2 gene. Mammalian Genome 2007, 18:270-276.
151. Wakefield L., Robinson J., Long H., Ibbit J.C., Cooke S., Hurst H.C., et al. Arylamine N-acetyltransferase I expression in breast cancer cell lines: A potential marker in estrogen receptor-positive tumors. Genes Chromosomes and Cancer 2008, 47:118-126.
152. Walraven J.M., Doll M.A., Hein D.W. Identification and characterization of functional rat arylamine N-acetyltransferase 3: comparisons with rat arylamine N-acetyltransferases 1 and 2. Journal of Pharmacology and Experimental Therapeutics 2006, 319:369-375.
153. Walraven J.M., Trent J.O., Hein D.W. Computational and experimental analyses of mammalian arylamine N-acetyltransferase structure and function. Drug Metabolism and Disposition 2007, 35:1001-1007.
154. Wang D., Para M.F., Koletar S.L., Sadee W. Human N-acetyltransferase 1*10 and *11 alleles increase protein expression through distinct mechanisms and associate with sulfamethoxazole-induced hypersensitivity. Pharmacogenetics and Genomics 2011, 21:652-664.
155. Wang H., Liu L., Hanna P.E., Wagner C.R. Catalytic mechanism of hamster arylamine N-acetyltransferase 2. Biochemistry 2005, 44:11,295-11,306.
156. Wang H., Vath G.M., Gleason K.J., Hanna P.E., Wagner C.R. Probing the mechanism of hamster arylamine N-acetyltransferase 2 acetylation by active site modification, site-directed mutagenesis, and pre-steady state and steady state kinetic studies. Biochemistry 2004, 43:8234-8246.
157. Wang H., Wagner C.R., Hanna P.E. Irreversible inactivation of arylamine N-acetyltransferases in the presence of N-hydroxy-4-acetylaminobiphenyl: a comparison of human and hamster enzymes. Chemical Research in Toxicology 2005, 18:183-197.
158. Ward A., Summers M.J., Sim E. Purification of recombinant human N-acetyltransferase type 1 (NAT1) expressed in E. coli and characterization of its potential role in folate metabolism. Biochemical Pharmacology 1995, 49:1759-1767.
159. Watanabe M., Sofuni T., Nohmi T. Involvement of cys69 residue in the catalytic mechanism of N-hydroxyarylamine O-acetyltransferase of Salmonella typhimurium. Sequence similarity at the amino acid level suggests a common catalytic mechanism of acetyltransferase for S. typhimurium and higher organisms. Journal of Biological Chemistry 1992, 267:8429-8436.
160. Watson A.P., Wang P.D., Sim E. Arylamine N-acetyltransferase from fast (C57BL6) and slow (A/J) N-acetylating strains of mice. Biochemical Pharmacology 1990, 39:647-654.
161. Weber W.W. Populations and genetic polymorphisms. Molecular Diagnostics 1999, 4:299-307.
162. Westwood I.M., Sim E. Kinetic characterisation of arylamine N-acetyltransferase from Pseudomonas aeruginosa. BMC Biochemistry 2007, 8:3.
163. Westwood I.M., Bhakta S., Russell A.J., Fullam E., Anderton M.C., Kawamura A., et al. Identification of arylamine N-acetyltransferase inhibitors as an approach towards novel anti-tuberculars. Protein Cell 2010, 1:82-95.
164. Westwood I.M., Holton S.J., Rodrigues-Lima F., Dupret J.M., Bhakta S., Noble M.E., et al. Expression, purification, characterization and structure of Pseudomonas aeruginosa arylamine N-acetyltransferase. Biochemical Journal 2005, 385:605-612.
165. Westwood I.M., Kawamura A., Fullam E., Russell A., Davies S.G., Sim E. Structure and mechanism of arylamine N-acetyltransferases. Current Topics in Medicinal Chemistry 2006, 6:1641-1654.
166. Westwood I.M., Kawamura A., Russell A.J., Sandy J., Davies S.G., Sim E. Novel small-molecule inhibitors of arylamine N-acetyltransferases: drug discovery by high-throughput screening. Combinatorial Chemistry and High Throughput Screening 2011, 14:117-124.
167. Wu H., Dombrovsky L., Tempel W., Martin F., Loppnau P., Goodfellow G.H., et al. Structural basis of substrate-binding specificity of human arylamine N-acetyltransferases. Journal of Biological Chemistry 2007, 282:30,189-30,197.
168. Yam K.C., D'Angelo I., Kalscheuer R., Zhu H., Wang J.X., Snieckus V., et al. Studies of a ring-cleaving dioxygenase illuminate the role of cholesterol metabolism in the pathogenesis of Mycobacterium tuberculosis. PLoS Pathogens 2009, 5:e1000344.
169. Zang Y., Doll M.A., Zhao S., States J.C., Hein D.W. Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2. Carcinogenesis 2007, 28:1665-1671.
170. Zhu Y., States J.C., Wang Y., Hein D.W. Functional effects of genetic polymorphisms in the N-acetyltransferase 1 coding and 3' untranslated regions. Birth Defects Research A: Clinical and Molecular Teratology 2011, 91:77-84.